ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1951

Elevated Level of Tumor Necrosis Factor-Like Weak Inducer of Apoptosis in Patients with Polymyositis or Dermatomyositis

Qinglin Peng, Xin Lu, Ning Zu, Lu Zhang and Guochun Wang, Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cytokines and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor (TNF) family, has emerged as a cytokine that regulates multiple cellular responses, including proinflammatory activity, angiogenesis and cell proliferation. Increased levels of TWEAK were observed in many types of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. However, information about TWEAK in polymyositis and dermatomyositis is limited.The aim of the present study was to investigate the expression of TWEAK in patients with polymyositis and dermatomyositis.

Methods: Twenty four patients with polymyositis, twenty two dematomyositis patients and twenty four healthy controls were recruited in the study. Serum levels of TWEAK were measured by ELISA. TWEAK messenger RNA (mRNA) expression in skeletal muscle from 19 out of 46 PM/DM patients and 11 healthy controls was detected by relative quantification RT-PCR. The results of two groups were compared using unpaired t test.

Results: Serum levels of TWEAK in PM/DM patients were significantly higher compared to healthy controls [(555.34±124.05)pg/ml vs (346.22±146.29)pg/ml, P<0.05]. However, there was no statistically significant difference between PM patients and DM patients[(533.34±119.67)pg/ml vs (579.25±127.06)pg/ml,P>0.05]. TWEAK mRNA in skeletal muscle showed a higher level in skeletal muscle of PM/DM patients than healthy controls, using GAPDH gene as reference gene .

Conclusion: The present study shows that serum levels and mRNA expression of TWEAK were elevated in patients PM/DM. TWEAK may possibly be enrolled in pathogenesis of PM/DM.


Disclosure:

Q. Peng,
None;

X. Lu,
None;

N. Zu,
None;

L. Zhang,
None;

G. Wang,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-level-of-tumor-necrosis-factor-like-weak-inducer-of-apoptosis-in-patients-with-polymyositis-or-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology